ClinicalTrials.gg
RecruitingNCT06469632RASDOPUpdated Jun 21, 2024

Radiofrequency and Myofascial Pain Syndrome in Postpartum Pelvic Pain

An interventional study of Active Comparator: Experimental Group 1 and Experimental: Experimental Group 2 in To be Approved by the Ethics Committee, sponsored by University of Alcala. Recruiting at 1 site in Spain. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2024-06-21.

Sponsored by University of Alcala · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2024, 2 years 1 month ago, but the record still lists the study as recruiting.
  • Registered 5 months after the study started (first participant enrolled Jun 2023, registered Dec 2023).
  • Started Jun 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
74
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Pelvic Pain with a site in Spain — 6 open to participants now, 6 under way, none of them phase 3. Pelvic Pain · Spain.

Planned enrollment
11th of 22
74 · median 69
Started
2023
with 2 others
No phase
16 of 27
5 open now
Registered
17th of 27
by date
Lead sponsor
3 of 27
University of Alcala

Among the 27 studies in Pelvic Pain with a site in Spain, this one is the 11th largest by planned enrollment of the 22 interventional ones that give a count, is one of 3 that started in 2023, is one of 16 with no phase, and was the 17th registered.

Pelvic Pain

377 studies on the registry are indexed under Pelvic Pain; 91 are open to participants now.

Browse Pelvic Pain studies →

Open to participants now

6 of the 27 studies in Pelvic Pain with a site in Spain are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 61 Pelvic Pain studies recruiting now, 22 (36%) set no upper age limit and 37 (61%) stop at 75 or younger; 5 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Pelvic Pain with a site in Spain, or all of them as a file.
02

Study summary

About 30% of women experience pain in the perineum and pelvic region one year after the vaginal labor, rising up to 50% when it is triggered during vaginal penetration, called this pain as dyspareunia. An early physiotherapy treatment could be the solution to the pain relief of these women. Thus, the objectives of the present randomised clinical trail are (i) to determine the effectiveness of a physiotherapy treatment based on education therapeutic, the treatment of myofascial pain syndrome (MPS) of the pelvic floor muscles (PFM), and PFM specific training with or without radiofrequency in reducing pain and improving sexual function; and, (ii) to know the facilitating factors and barriers in adherence and perceived self-efficacy towards physiotherapy treatment of women with pelviperineal pain in the postpartum.

Methodology: randomized clinical trial with examinator blinding and two parallel groups, followed by a qualitative study. Thirty eight women per group will be needed with postpartum pelviperineal pain between 8 weeks after labour, with intensity ≥ 4 cm on the visual analogue scale. The assignment will be random to an Experimental 1 group based on therapeutic education, plus conservative and invasive treatment of MPS and specific PFM exercise versus an Experimental 2 group consisted in the same treatment plus non-ablative radiofrequency treatment. In both cases, 12 individual supervised sessions will be held by a physiotherapist specialized in women's health, with evaluations pre- and post-intervention, at 3 and 6 months. The outcome variables will be the intensity of the pain, the presence of MPS at PFM, the PFM contraction quality, sexual function and specific quality of life. The qualitative study will be carried out in the assessment 6 months post-intervention, through interviews semi-structured and focus groups. The interviews will be guided with previous questions established, recorded, transcribed and thematically analyzed by a panel of experts.

03

Conditions studied

  • To be Approved by the Ethics Committee

Keywords

  • Pelvic Pain
  • Physiotherapy
  • Therapeutic adherence
  • Postpartum
  • Pelvic floor
  • Radiofrequency
  • Myofascial Pain Syndrome
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Primiparous women
  • Eutocic vaginal birth
  • Postpartum pelviperineal pain 8 weeks after birth
  • Intensity ≥ 4 cm in the VAS
  • Freely signed the

Exclusion criteria

Exclusion Criteria:

  • Multiparous women
  • Instrumental delivery
  • Cesarean delivery
  • Avulsion of the levator ani muscle
  • Diagnosis of coccygodynia and/or coccygeal pain
  • Sphincter anal injury during vaginal birth
  • History of pelvic fractures and/or neoplasms
  • Pregnant women
  • Neurological diseases
  • Vaginal infection or active urinary tract, or with any
  • Uterine device with metallic components
  • Women with cognitive, auditory and/or visual limitations to understand information, respond to questionnaires, consent and/or participate in the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
74 participants (estimated)

Study arms

  • Active comparator
    Experimental Group 1

    There will be 12 individual sessions guided by a physiotherapist specialized in Women's Health. The approximate duration will be 45 minutes/session, 2 times a week for 6 weeks. The intervention will consist of a multimodal physiotherapy treatment based on therapeutic patient education, specific PFM exercises, and conservative and invasive treatment of the MPS. Pre- and post-intervention assessments will be carried out, and at 3 and 6 months after the intervention, by an examining physiotherapist who will be blinding for the intervention group.

    Other: Active Comparator: Experimental Group 1

  • Experimental
    Experimental Group 2

    There will be 12 individual sessions guided by a physiotherapist specialized in Women's Health. The approximate duration will be 45 minutes/session, 2 times a week for 6 weeks. The intervention will consist of a multimodal physiotherapy treatment based on therapeutic patient education, specific PFM exercises, conservative and invasive treatment of the MPS and non-ablative radiofrequency. Pre- and post-intervention assessments will be carried out, and at 3 and 6 months after the intervention, by an examining physiotherapist who will be blinding for the intervention group.

    Other: Experimental: Experimental Group 2

Interventions

  • OtherActive Comparator: Experimental Group 1

    Multimodal physiotherapy treatment composed of: Therapeutic education about anatomy, physiology and pathophysiology of the abdomino-pelvic cavity, pelvic floor dysfunctions and risk factors, the concept of pain and its associated factors, as well as individual strategies to manage pain. Specific PFM exercises performing different types of contractions aimed at improving proprioception, strength, resistance and relaxation capacity. Conservative and invasive treatment of MPS active myofascial trigger points (MTP) will be treated by dry needling and Swiss technique. Latent MTP will be treated using the Swiss technique.

  • OtherExperimental: Experimental Group 2

    Multimodal physiotherapy treatment composed of: Therapeutic education about anatomy, physiology and pathophysiology of the abdomino-pelvic cavity, pelvic floor dysfunctions and risk factors, the concept of pain and its associated factors, as well as individual strategies to manage pain. Specific PFM exercises performing different types of contractions aimed at improving proprioception, strength, resistance and relaxation capacity. Conservative and invasive treatment of MPS active myofascial trigger points (MTP) will be treated by dry needling and Swiss technique. Latent MTP will be treated using the Swiss technique. Non-ablative radiofrequency: using capacitive superficial electrodes and resistive superficial and intravaginal electrodes.

06

What researchers measure

Primary outcomes

  1. Pain intensity through the Verbal Numerical Scale (0 no pain, and 10 the most bearable pain)

    intensity, behavior and location (pain body chart).

    Time frame: Pre-treatment, post-treatment (6 weeks after starting the study), 3 and 6 months after treatment

  2. Sexual function

    Self-completion of the FSFI questionnaire, which evaluates sexual function based on 6 domains: desire, excitement, lubrication, orgasm, satisfaction and pain. The maximum score is 36, considering sexual dysfunction a value \>27.

    Time frame: Pre-treatment, post-treatment (6 weeks after starting the study), 3 and 6 months after treatment

Secondary outcomes

  1. Pelvic floor dysfunction symptoms

    Presence of urinary, intestinal and/or symptoms suggestive of prolapse

    Time frame: Pre-treatment, post-treatment (after 12 sessions of physiotherapy treatment which will last approximately 3 months after starting the study), 3 and 6 months after treatment

  2. PFM capacity of contraction through Modified Oxford Scale (0 no contraction, 5 strong contraction)

    Intravaginal palpation of pelvic floor muscles with one or two fingers.

    Time frame: Pre-treatment, post-treatment (6 weeks after starting the study), 3 and 6 months after treatment

  3. PFM capacity of relaxation (yes or no)

    Intravaginal palpation of pelvic floor muscles with one or two fingers.

    Time frame: Pre-treatment, post-treatment (6 weeks after starting the study), 3 and 6 months after treatment

  4. PFM basal tone in grams

    Intravaginal dynamometry

    Time frame: Pre-treatment, post-treatment (6 weeks after starting the study), 3 and 6 months after treatment

  5. PFM muscle strength in grams

    Intravaginal dynamometry

    Time frame: Pre-treatment, post-treatment (6 weeks after starting the study), 3 and 6 months after treatment

  6. Distance of the urogenital hiatus in milimeters

    Assessment through transperineal ultrasound of the distance of the urogenital hiatus at rest, during a strong PFM contraction and during a pushing effort.

    Time frame: Pre-treatment, post-treatment (6 weeks after starting the study), 3 and 6 months after treatment

  7. Presence of MPS in PFM and abdominal muscles

    Following the diagnostic criteria of Travel and Simons.

    Time frame: Pre-treatment, post-treatment (6 weeks after starting the study), 3 and 6 months after treatment

  8. Specific quality of life and impact of Pelvoc floor Disfunction using questionnaires: PFDI-20 and PFIQ-7

    Through the questionnaires: Pelvic Floor Distress Inventory short version (PFDI-20) and Pelvic Floor Impact Questionnaire short form (PFIQ-7). In both questionnaires, the scores range between 0 and 300, where a higher score indicates more distress and more impact on quality of life.

    Time frame: Pre-treatment, post-treatment (6 weeks after starting the study), 3 and 6 months after treatment

  9. Self-efficacy

    Through Broome Pelvic Muscle Self-Efficacy Scale. The score ranges from 0 to 100, where 100 implies greater self-efficacy.

    Time frame: Pre-treatment, post-treatment (6 weeks after starting the study), 3 and 6 months after treatment

07

Study locations

1 of 1 sites recruiting
  • Physiotherapy in Women's Health (FPSM) Research Group. Physiotherapy Department, Faculty of Medicine and Health Sciences, University of Alcalá, Alcalá de Henares, 28805 Madrid, Spain.
    Alcalá de Henares, Madrid 28871, Spain
    Recruiting
    • Beatriz Navarro- Brazález, PhD · Contactb.navarro@uah.es · +34-91-885-48-28
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Oct 2024, 16 months after the start.

Of 110 non-industry interventional studies with no phase under Pelvic Pain, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 30. This study's planned 16 months is close to that.

Counting every sponsor, half of 114 studies reached it within 17 months; a quarter within 5 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2023
First posted
Jun 21, 2024
StartActual
Jun 27, 2023
Primary completionEst.
Oct 2024
CompletionEst.
Nov 2025
Last update
Jun 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06469632
Responsible party
Beatriz Navarro Brazález (Assistant PhD Professor, University of Alcala) — Principal investigator
First posted
Jun 21, 2024
Start date
Jun 27, 2023
Primary completion
Oct 2024 (estimated)
Completion
Nov 2025 (estimated)
Last update
Jun 21, 2024

Study contacts

Beatriz Navarro-Brazález, PhD
Contact
b.navarro@uah.es
+34918854828 ext. 4828
Beatriz Navarro-Brazález, PhD
principal investigator · Physiotherapy in Women's Health (FPSM) Research Group. Physiotherapy Department, Faculty of Medicine and Health Sciences, University of Alcalá, Alcalá de Henares, 28805 Madrid, Spain.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion